What is KPV?
KPV is a three-amino-acid peptide investigated in intestinal and immune-cell research. Its short sequence does not make clinical efficacy self-evident.
Video overview · 3:04
KPV Peptide: Gut Inflammation, Skin and the FDA Vote. What the Research Shows
Where the three-amino-acid KPV fragment comes from, how it acts in cells, the mouse colitis studies, why it has never been tested in people, and its FDA, compounding and anti-doping status.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
KPV is a tiny peptide, just three amino acids, sold online for gut inflammation, skin and immune health. In July, an FDA advisory panel voted to recommend letting pharmacies make it. But the research behind it is all in cells and animals. Here's what's actually known.
KPV stands for lysine, proline and valine. It's the last three amino acids of alpha-MSH, a natural hormone involved in skin pigment and inflammation. In the 1980s, researchers found this tiny fragment could reduce fever in rabbits and ear swelling in mice.
In lab studies, KPV enters gut-lining and immune cells through a transporter called PepT1, then turns down NF-kappa-B, a switch for inflammation. Unlike its parent hormone, it doesn't seem to act through melanocortin receptors. The FDA says its exact targets remain unknown.
In 2008, two mouse studies found KPV reduced chemically induced colitis, with less inflammation and faster weight recovery. A 2016 study found it prevented colitis-related tumors in mice, but not in mice lacking PepT1. And a 2017 study packed it into nanoparticles aimed at inflamed colons in mice.
Outside the gut, all eight KPV-treated rabbit eyes with scratched corneas had healed at 60 hours, versus none on placebo. In airway cells, it blocked the same inflammation switch. And on human skin samples in a lab, KPV barely got through unless it was pushed in with microneedles or a mild electric current.
In people, there's nothing. We found no published human trial or case report, and no registered trial. The FDA says it has not identified any clinical studies or human exposure data for KPV by any route.
KPV is not FDA approved. Reviewing it for wound healing and inflammatory conditions, FDA staff recommended against the compounding list: no human safety data, no toxicity studies, and no data on impurities or immune reactions. In July, the advisory panel voted eight to six, with one abstention, to recommend it anyway. That vote is advisory, and the FDA hasn't acted.
Does KPV treat gut inflammation in people? Unproven: only cell and mouse studies. Is it safe? Unknown: there's no human safety data at all. Did the FDA approve it? No. And can pharmacies make it now? Not yet: the panel vote is only a recommendation.
The bottom line: KPV is a tiny fragment of a natural hormone that calms inflammation in cells and in mice with colitis. It has never been tested in people, its safety is unknown, and it isn't approved. For every study and source, see the KPV profile on PepsRadar dot com.
Biological role or research focus
Inflammatory signaling in intestinal research.
Cell and mouse colitis experiments do not establish an effective treatment for human inflammatory bowel disease.
Role reference: PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. ↗
- Class / identity
- Lysine–proline–valine tripeptide
- Main research area
- Intestinal inflammatory signaling
- Evidence featured
- Cell and mouse experiments
- Source check
- October 4, 2026
Source: PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. ↗
Quick answers
- Is KPV FDA approved?
- No. No FDA-approved drug contains KPV. Source ↗
- Is KPV safe?
- KPV is an unapproved tripeptide with no human exposure data. FDA says the safety risks of using it in people are unknown. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
- Is KPV banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
- Has the FDA taken action over KPV?
- Yes. Our records list 2 FDA actions naming it, most recently on October 28, 2026: HHS filed an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Federal Register 2026-22192, published October 30, 2026; RIN 0910-ZD94). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| PepT1 and intestinal inflammation (2008) | Cell and mouse experiments | Intestinal epithelial and immune cells, plus two chemically induced mouse-colitis models. |
| Targeted KPV nanoparticles (2017) | Animal / laboratory study | Intestinal cell experiments and a mouse colitis model. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Cell and mouse experiments · 2008
PepT1 and intestinal inflammation
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
- Population / model
- Intestinal epithelial and immune cells, plus two chemically induced mouse-colitis models.
- Study design
- Transport assays, inflammatory signaling measurements, and oral exposure in mice.
- Main finding
- KPV uptake involved PepT1; inflammatory signaling and cytokine release decreased. Colitis measures improved in the mouse experiments.
- Limits & context
- The experiments support a transport/mechanism hypothesis. They do not establish clinical remission, mucosal healing, or a safe treatment regimen in people with inflammatory bowel disease.
Source: PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. ↗
Animal / laboratory study · 2017
Targeted KPV nanoparticles
Did an engineered delivery system change experimental colitis outcomes?
- Population / model
- Intestinal cell experiments and a mouse colitis model.
- Study design
- KPV in hyaluronic-acid-coated nanoparticles within a hydrogel was compared with a nanoparticle system without the same targeting coating.
- Main finding
- The targeted system delivered KPV to epithelial cells and macrophages. In mice, it reduced mucosal damage and TNF-alpha more strongly than the comparison delivery system.
- How to read it
- Delivery technology was central to the experiment; these were not ordinary KPV capsules or vials.
- Limits & context
- This is preclinical evidence, not a clinical ulcerative-colitis trial. Cell compatibility does not establish human safety, and the findings cannot be transferred to a different formulation or route.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming KPV as an intervention was found on ClinicalTrials.gov when we last checked (October 15, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Search additional PubMed records ↗Risks & interactions
KPV is an unapproved tripeptide with no human exposure data. FDA says the safety risks of using it in people are unknown.
FDA's 2026 review found no human data for any route, including on immune reactions or aggregation. Evidence comes from cell and mouse colitis experiments.
Unassessed: no human safety data
It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA briefing document: KPV (Pharmacy Compounding Advisory Committee, 2026) ↗ · FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · PepT1-mediated KPV uptake reduces intestinal inflammation (2008) ↗
Safety evidence & remaining uncertainty
FDA has identified a human-exposure evidence gap. Laboratory transport and inflammation assays do not resolve human tolerability or interactions.
Source: FDA · Peptide compounding safety concerns ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "KPV". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. FDA presented KPV (free base and acetate) to its Pharmacy Compounding Advisory Committee on July 23, 2026, proposing that it NOT be added to the 503A bulks list. On October 28, 2026, HHS filed an interim enforcement discretion policy covering KPV (Federal Register 2026-22192): HHS does not intend to act against state-licensed pharmacies, federal facilities or licensed physicians compounding it while rulemaking proceeds. That is not listing on the 503A bulks list and not FDA approval. source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
FDA actions
- HHS filed an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Federal Register 2026-22192, published October 30, 2026; RIN 0910-ZD94). KPV is one of six peptides in its Appendix A (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500). HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding with these peptides while FDA develops the 503A bulks list by rulemaking. It is not an FDA approval, does not add KPV to the 503A bulks list, is not binding, and HHS may revisit it if a safety signal or quality problem arises. The comment period on regulations.gov closed on November 13, 2026 (docket HHS-OASH-2026-0496). (2026-10-28) source
- FDA presented KPV (free base and acetate) to its Pharmacy Compounding Advisory Committee (July 23, 2026) for possible addition to the 503A bulks list; FDA's briefing document proposed NOT adding it. The committee's vote is advisory; no final FDA decision found. (2026-07) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
This is preclinical inflammation research. Mouse-colitis findings cannot establish treatment of Crohn disease, ulcerative colitis, or nonspecific digestive symptoms in people.
Source: PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
The selected work links cellular uptake through PepT1 to reduced inflammatory signaling. It combines transport experiments with chemically induced colitis models.
Source: PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. ↗
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- Cell and mouse colitis experiments do not establish an effective treatment for human inflammatory bowel disease.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Was the study a human inflammatory-bowel-disease trial?
No. It used cultured cells and mouse models.
Source: PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. ↗
Does reduced cytokine expression prove symptom relief?
No. Molecular markers, tissue healing, symptom control, and sustained remission are different endpoints.
Source: PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. ↗
References & editorial record
- FDA · Compounding safety concerns ↗
- PubMed · Cells and mouse colitis models · PMID 18061177 ↗
- Targeted KPV nanoparticles · 2017 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
Tissue repair peptides: which have actually been tested in people?
A roundup of popular tissue repair peptides and what has been tested in people: BPC-157's tiny human record, thymosin beta-4 eye and ulcer trials, GHK-Cu skin studies, TP-508 and LL-37 wound trials, plus FDA and WADA status.
Read the guide →RESEARCH FIELD GUIDE
Which peptides can pharmacies compound now? The 2026 HHS peptide policy explained
HHS says it will not act against licensed 503A compounders using six peptides while FDA writes its bulks-list rules. That is not FDA approval, and FDA staff found little or no human data for any of the six.
Read the guide →

